EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Adenosine receptor A2b confers ovarian cancer survival and PARP inhibitor resistance through IL‐6‐STAT3 signalling

Liqing Chi iD, Lin Huan, Chunyan Zhang, Hanming Wang, Jian Lu

Journal of Cellular and Molecular Medicine · 2023-08 · 27 (15) · 2150-2164

DOI: 10.1111/jcmm.17802 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 06.06.2023. Verfasst von Liqing Chi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular Medicine, College of Future Technology, Peking University, Beijing, China. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ovarian cancer is the deadliest gynecologic cancer worldwide, and the therapeutic options are limited. PARP inhibitor (PARPi) represents an effective therapeutic strategy and has been approved for maintenance therapy. However, the intrinsic or acquired resistance to PARPi becomes a big challenge. To investigate the mechanisms for PARPi resistance, we analysed public databases and established Olaparib‐resistant ovarian cancer cells for exploration. Our results showed that the inflammatory pathway and adenosine receptor A2b ( Adora2b /A 2B ) expression were significantly increased in Olaparib‐resistant cells. A 2B was highly expressed in recurrent ovarian tumours and negatively correlated with the clinical outcomes in cancer patients. Olaparib treatment enhanced A 2B expression through NF‐κB activation. The elevated A 2B contributed to Olaparib resistance by sensing adenosine signal and promoting tumour cell survival, growth and migration via IL‐6‐STAT3 signalling. Therefore, inhibition of A 2B ‐IL‐6‐STAT3 axis could overcome Olaparib resistance and synergize with Olaparib to reduce cancer cell growth and lead to cell death. Our findings reveal a critical role of A 2B signalling in mediating PARPi resistance independent of DNA damage repair, providing insights into developing novel therapies in ovarian cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsAntineoplastic AgentsHumansFemalePoly(ADP-ribose) Polymerase InhibitorsInterleukin-6Neoplasm Recurrence, LocalReceptors, Purinergic P1PhthalazinesCell Line, TumorSTAT3 Transcription Factor

Stichwörter der Autor:innen

Adora2bIL-6-STAT3 signallingPARPi resistanceadenosineovarian cancer

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsInterleukin-6Antineoplastic AgentsReceptors, Purinergic P1PhthalazinesSTAT3 protein, humanSTAT3 Transcription Factor

Autor:innen und Institutionen

  • Institute of Molecular Medicine, College of Future Technology, Peking University, Beijing, China.
  • Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.

ORCID-Profile: Liqing Chi

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Chi, L., Huan, L., Zhang, C., Wang, H., & Lu, J. (2023). Adenosine receptor A2b confers ovarian cancer survival and PARP inhibitor resistance through IL‐6‐STAT3 signalling. Journal of Cellular and Molecular Medicine, 27(15), 2150-2164. https://doi.org/10.1111/jcmm.17802

Vancouver

Chi L, Huan L, Zhang C, Wang H, Lu J. Adenosine receptor A2b confers ovarian cancer survival and PARP inhibitor resistance through IL‐6‐STAT3 signalling. Journal of Cellular and Molecular Medicine. 2023;27(15):2150-2164. doi:10.1111/jcmm.17802

BibTeX
@article{Chi2023,
  author = {Chi, Liqing and Huan, Lin and Zhang, Chunyan and Wang, Hanming and Lu, Jian},
  title = {Adenosine receptor A2b confers ovarian cancer survival and PARP inhibitor resistance through IL‐6‐STAT3 signalling},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2023},
  volume = {27},
  number = {15},
  pages = {2150--2164},
  doi = {10.1111/jcmm.17802}
}
Kostenlos starten →